TY - JOUR
T1 - The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease:
T2 - British Society for Rheumatology guideline scope
AU - Hannah, Jennifer
AU - Rodziewicz, Mia
AU - Mehta, Puja
AU - Heenan, Kerri-Marie
AU - Ball, Elizabeth
AU - Barratt, Shaney
AU - Carty, Sara
AU - Conway, Richard
AU - Cotton, Caroline V
AU - Cox, Sarah
AU - Crawshaw, Anjali
AU - Dawson, Julie
AU - Desai, Sujal
AU - Fahim, Ahmed
AU - Fielding, Carol
AU - Garton, Mark
AU - George, Peter M
AU - Gunawardena, Harsha
AU - Kelly, Clive
AU - Khan, Fasihul
AU - Koduri, Gouri
AU - Morris, Helen
AU - Naqvi, Marium
AU - Perry, Elizabeth
AU - Riddell, Claire
AU - Santos, Cristiana Sieiro
AU - Spencer, Lisa G
AU - Chaudhuri, Nazia
AU - Nisar, Muhammad K
PY - 2024/5/17
Y1 - 2024/5/17
N2 - Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.
AB - Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.
UR - https://doi.org/10.1093/rap/rkae056
U2 - 10.1093/rap/rkae056
DO - 10.1093/rap/rkae056
M3 - Article (Academic Journal)
C2 - 38765189
SN - 2514-1775
VL - 8
JO - Rheumatology Advances in Practice
JF - Rheumatology Advances in Practice
IS - 2
M1 - rkae056
ER -